Bayer has seen its share price surge in recent months, which puts fresh attention on whether the current valuation lines up with what the company is generating in sales. With the stock now reflecting a series of business updates across its pharmaceutical and crop science operations, the question is how much of those revenue prospects are already embedded in the price.
-
The stock is up 105.8% over the past year. Any investor stepping in today is effectively considering whether the business can support that move through its sales profile.
-
Recent news on prostate cancer drug NUBEQA and other therapies, along with partnerships such as the VERQUVO commercialization deal in Canada, can influence expectations for future revenue scale and the timing of cash coming off Bayer’s pipeline.
-
There is a second opinion on Bayer worth weighing. See what analysts think Bayer’s shares could be worth.
The issue now is whether Bayer’s current share price is adequately supported by the sales it generates today and what the market expects those sales to look like over time.
This kind of sales question is not unique to Bayer. If you want to compare how other businesses are priced against their fundamentals, scan our 194 high quality undervalued stocks.
Is Bayer a Bargain on Sales?
P/S is a clean way to look at Bayer because the group still reports losses on a P/E basis, yet it has a sizeable revenue base across pharmaceuticals and crop science. On this metric, the stock trades on a P/S of about 1.2x, which is well below the broader pharmaceuticals industry average of 2.5x and also under the peer group on roughly 4.0x.
The fair P/S ratio implied by Bayer’s own profile, which takes into account its growth outlook, margins, size and risk mix, sits higher than where the shares trade today. As a result, the current 1.2x screens as undervalued on this tailored yardstick. Because Bayer recently raised its 2026 profit forecast on a recovery in the pharma division, that discount on sales comes despite sentiment support from drugs such as NUBEQA and KERENDIA. Explore the numbers behind Bayer’s P/S valuation.
The Bayer Narrative: What Would Justify Today’s Price?
Narratives for Bayer pick up where the P/S puzzle leaves off. They spell out which paths on revenue, profitability and earnings would need to play out for the current share price to look either stretched or conservative, based on clear forward-looking assumptions. Where a single valuation ratio gives one number, these outlines describe the future that number leans on so you can watch whether reality tracks the story set out on Simply Wall St’s Community page.
